Ozempic vs Wegovy: Same Molecule, and the Diabetes Label Costs More

Last reviewed 25 August 2026 · Educational, not medical advice · No sponsorships, no affiliate links

The 0.4 mg question, answered properly

Ozempic tops out at 2 mg a week. Wegovy tops out at 2.4 mg, or 7.2 mg since the high-dose version was approved in March 2026. People see 6% weight loss attached to one and 14.9% attached to the other and conclude the last 0.4 mg is doing extraordinary work. It is not.

The dose-response curve for semaglutide is real but gentle at the top end. The larger effect is the population. Weight-loss response to GLP-1 drugs is consistently blunted in type 2 diabetes, and it shows up wherever the same drug has been tested in both groups. Semaglutide 2.4 mg produced 14.9% weight loss in STEP-1, in people without diabetes, and about 9.6% in STEP-2, in people with it - identical drug, identical dose, a third less weight lost. Tirzepatide shows the same pattern between SURMOUNT-1 and SURMOUNT-2.

So when someone tells you Ozempic is "weaker for weight loss," the accurate version is: Ozempic was studied in a group that responds less, at a dose 17% lower, for endpoints that were about blood sugar. None of those three things is a property of the molecule.

The practical consequence still holds, though. If your goal is weight and you can access either, Wegovy is the correct product, because it is the one licensed to be titrated into the range where the weight-loss trials were run.

The diabetes label is the expensive one

Through NovoCare, Novo Nordisk’s cash-pay channel, both products start at $349 a month as of August 2026, with a $199 introductory rate on the two lowest doses running to 31 December 2026. But the ladders end differently. Wegovy holds $349 at every standard dose through 2.4 mg. Ozempic holds $349 through 1 mg and then steps to $499 at 2 mg.

Read that again, because it inverts the usual assumption. At the top of each ladder - which is where anyone on maintenance actually lives - the diabetes drug costs $150 a month more than the weight-loss drug, and they are the same molecule. A year at Ozempic 2 mg runs $1,800 above a year at Wegovy 2.4 mg for a smaller dose of identical semaglutide.

Through insurance, they are barely the same category. Ozempic carries a diabetes indication and is covered by most commercial plans and by Medicare Part D. Wegovy carries a weight-management indication, which a large share of US plans still exclude outright and Medicare has historically not covered for obesity alone. That asymmetry - not efficacy - is what drives most of the off-label Ozempic prescribing you hear about, and it is why the same molecule can cost one person $25 and the person next to them $349.

Wegovy’s cardiovascular indication, granted in March 2024 on the strength of the SELECT trial, was partly an answer to this. A drug that prevents heart attacks is harder for a plan to dismiss as cosmetic. Coverage has loosened since, unevenly.

Where the labels genuinely diverge

The indications are not interchangeable, and this is the one place the brand choice carries real clinical content rather than paperwork.

• Ozempic holds type 2 diabetes, cardiovascular risk reduction in type 2 diabetes with established heart disease, and chronic kidney disease in type 2 diabetes, the last on the strength of the FLOW trial. A peripheral artery disease indication has been recommended in the EU following STRIDE.
• Wegovy holds chronic weight management, cardiovascular risk reduction in overweight or obesity without diabetes (SELECT: 20% fewer major adverse cardiac events across 17,604 patients), and accelerated approval from August 2025 for MASH with moderate-to-advanced fibrosis - the first GLP-1 drug approved for a liver indication.

If you have diabetic kidney disease, Ozempic is the product with the label. If you have MASH, Wegovy is. The molecule does not care, but prescribers, pharmacists, and prior-authorisation reviewers do.

Wegovy HD and the Wegovy pill changed the shape of this comparison

Two 2026 additions matter more than the Ozempic-versus-Wegovy question they sit inside.

Wegovy HD at 7.2 mg, approved by the FDA in March 2026, reached 20.7% weight loss at 72 weeks in the STEP UP trial, against 17.5% for 2.4 mg and 2.4% for placebo. That figure is statistically indistinguishable from the 20.2% tirzepatide achieved in SURMOUNT-5 - a different trial, so not a valid direct comparison, but enough to say the assumption that semaglutide simply cannot reach tirzepatide territory no longer holds at the new ceiling.

The Wegovy pill, oral semaglutide 25 mg, was approved on 22 December 2025 and launched in January 2026. In OASIS-4 it produced 13.6% weight loss on the treatment-policy basis, close to the injection. The cost is a daily ritual: it must be taken on an empty stomach with a 30-minute wait before food, drink, or any other oral medication. That constraint is the entire competitive gap between it and Foundayo, which has none.

Tracking answers the question this comparison cannot

This whole page is about a dose ceiling and a trial population. Neither is a fact about you. If you are on Ozempic and still losing at 2 mg, the ceiling is not your constraint and switching products buys you nothing; if you flattened at 1 mg and never moved again, that is worth knowing before you assume 2.4 mg would have been different. Only your own dose-response curve settles it, and you cannot read a curve you never plotted.

Log weight weekly at a fixed time, and log every dose change with its date. Judge each step on four to six weeks of data, not on the first week, because appetite suppression lags a dose increase and so does the scale.Zenday App, our top-ranked GLP-1 companion at 4.55/5, keeps the dose schedule, food, and side-effect days in a single log for precisely this reason - the numbers are only useful next to the ladder that produced them.

There is a second, more mercenary reason to keep records here. Wegovy is the product US plans most often exclude, and prior authorisations and appeals are won on documentation. A dated record of doses, weights, and comorbidities is evidence in a way that a recollection is not. Shotsy builds a clinician-ready PDF export for exactly that handoff, which is why it sits second in ourGLP-1 app ranking despite a narrower feature set. If you expect a fight with your insurer, start the paper trail with the first injection rather than after the first denial.

What the evidence does not show

• No trial has compared Ozempic against Wegovy. There would be no point: same molecule. Every comparison of the two is a comparison of separate trials in separate populations.
• Nothing establishes that 2 mg and 2.4 mg differ meaningfully for an individual. The population-level dose response is documented; the 0.4 mg step is not where the headline difference comes from.
• Wegovy HD has no cardiovascular outcome trial of its own. SELECT tested 2.4 mg.

How to choose

• You have type 2 diabetes: Ozempic. It has the indication, the coverage, and the kidney data.
• You want weight loss and have no diabetes: Wegovy, because it is licensed into the dose range the weight trials used.
• You have both: a real decision, usually settled by which one your plan will pay for. The molecule is identical either way.
• You are paying cash and heading for a maintenance dose: Wegovy at 2.4 mg is $150 a month cheaper than Ozempic at 2 mg, for more of the same drug. If both are clinically appropriate, that is not a close call.
• You want more weight loss than 2.4 mg gives: ask about Wegovy HD 7.2 mg before you consider switching molecules. If you still want to switch, see semaglutide to tirzepatide.

Method and sources

Efficacy figures come from the STEP-1, STEP-2, STEP UP, SELECT, and OASIS-4 trials as published. Prices are US manufacturer self-pay rates published by NovoCare and read on 25 August 2026; self-pay pricing in this category has changed several times a year since 2024. We take no money from Novo Nordisk or any other manufacturer and run no affiliate links. For the underlying molecule comparison, see semaglutide vs tirzepatide; for the obesity-labelled products head to head, see Wegovy vs Zepbound.